Download PDF
Thromb Haemost 1997; 77(01): 137-142
DOI: 10.1055/s-0038-1655921
Fibrinolysis
Schattauer GmbH Stuttgart

Enhancement of Plasminogen Binding to U937 Cells and Fibrin by Complestatin

Kiyoshi Tachikawa
The Department of Applied Biological Science, Tokyo Noko University, Fuchu, Tokyo, Japan
,
Keiji Hasurni
The Department of Applied Biological Science, Tokyo Noko University, Fuchu, Tokyo, Japan
,
Akira Endo
The Department of Applied Biological Science, Tokyo Noko University, Fuchu, Tokyo, Japan
› Author Affiliations
Further Information

Publication History

Received 16 January 1996

Accepted after resubmisssion 30 September 1996

Publication Date:
11 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Plasminogen binds to endothelial and blood cells as well as to fibrin, where the zymogen is efficiently activated and protected from inhibition by α2-antiplasmin. In the present study we have found that complestatin, a peptide-like metabolite of a streptomyces, enhances binding of plasminogen to cells and fibrin. Complestatin, at concentrations ranging from 1 to 5 μM, doubled 125I-plasminogen binding to U937 cells both in the absence and presence of lipoprotein(a), a putative physiological competitor of plasminogen. The binding of 125I-plasminogen in the presence of complestatin was abolished by e-aminocaproic acid, suggesting that the lysine binding site(s) of the plasminogen molecule are involved in the binding. Equilibrium binding analyses indicated that complestatin increased the maximum binding of 125I-plasminogen to U937 cells without affecting the binding affinity. Complestatin was also effective in increasing 125I-plasminogen binding to fibrin, causing 2-fold elevation of the binding at ~1 μM. Along with the potentiation of plasminogen binding, complestatin enhanced plasmin formation, and thereby increased fibrinolysis. These results would provide a biochemical basis for a pharmacological stimulation of endogenous fibrinolysis through a promotion of plasminogen binding to cells and fibrin.

 

  • References

  • 1 Robbins KC, Summaria L, Hsieh B, Shah RJ. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J Biol Chem 1967; 242: 2333-2342
    PubMedGoogle Scholar
  • 2 Váli Z, Patthy L. Location of the intermediate and high affinity w-amino– carboxylic acid-binding sites in human plasminogen. J Biol Chem 1982; 257: 2104-2110
    PubMedGoogle Scholar
  • 3 Hajjar KA, Harpel PC, Jaffe EA, Nachman RL. Binding of plasminogen to cultured human endothelial cells. J Biol Chem 1986; 261: 11656-11662
    PubMedGoogle Scholar
  • 4 Miles LA, Plow EF. Plasminogen receptors: ubiquitous sites for cellular regulation of fibrinolysis. Fibrinolysis 1988; 02: 61-71
    PubMedGoogle Scholar
  • 5 Blasi F. Surface receptors for urokinase plasminogen activator. Fibrinolysis 1988; 2: 73-84
    PubMedGoogle Scholar
  • 6 Miles LA, Plow EF. Binding and activation of plasminogen on the platelet surface. J Biol Chem 1985; 260: 4303-4311
    PubMedGoogle Scholar
  • 7 Plow EF, Freaney DE, Plescia J, Miles LA. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1986; 103: 2411-2420
    CrossrefPubMedGoogle Scholar
  • 8 Stephens RW, Pöllänen J, Tapiovaara H, Leung K-C, Sim P-S, Salonen E-M, RØnne E, Behrendt N, DanØ K, Vaheri A. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol 1989; 108: 1987-1995
    CrossrefPubMedGoogle Scholar
  • 9 Anonick PK, Gonias SL. Soluble fibrin preparations inhibit the reaction of plasmin with α2-macroglobulin. Comparison with α2-antiplasmin and leupeptin. Biochem J 1991; 275: 53-59
    CrossrefPubMedGoogle Scholar
  • 10 Hall SW, Humphries JE, Gonias SL. Inhibition of cell surface receptor-bound plasmin by α2-antiplasmin and α2-macroglobulin. J Biol Chem 1991; 266: 12329-12336
    PubMedGoogle Scholar
  • 11 Berg K. A new serum type system in man - the Lp system. Acta Pathol Microbiol Scand 1963; 59: 369-382
    PubMedGoogle Scholar
  • 12 McLean JW, Tomlinson JE, Kuang W-J, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330: 132-137
    CrossrefPubMedGoogle Scholar
  • 13 Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989; 339: 301-303
    CrossrefPubMedGoogle Scholar
  • 14 Hajjar KA, Gavish D, Breslow JL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 339: 303-305
    CrossrefPubMedGoogle Scholar
  • 15 Gonzalez-Gronow M, Edelberg JM, Pizzo SV. Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein(a) competes for the same site. Biochemistry 1989; 28: 2374-2377
    CrossrefPubMedGoogle Scholar
  • 16 Kluft C, Jie AFH, Los P, de witE, Havekes L. Functional analogy between lipoprotein(a) and plasminogen in the binding to the kringle 4 binding protein, tetranectin. Biochem Biophys Res Commun 1989; 161: 427-433
    CrossrefPubMedGoogle Scholar
  • 17 Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990; 10: 240-245
    CrossrefPubMedGoogle Scholar
  • 18 Rouy D, Koschinsky ML, Fleury V, Chapman J, Anglϩs-Cano E. Apolipo-protein(a) and plasminogen interact with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments. Biochemistry 1992; 31: 6333
    CrossrefPubMedGoogle Scholar
  • 19 Ezratty A, Simon DI, Loscalzo J. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry 1993; 32: 4628-4633
    CrossrefPubMedGoogle Scholar
  • 20 Seto H, Fujioka T, Furihata K, Kaneko I, Takahashi S. Structure of complestatin, a very strong inhibitor of protease activity of complement in the human complement system. Tetrahedron Lett 1989; 30: 4987-4990
    CrossrefPubMedGoogle Scholar
  • 21 Kaneko I, Kamoshida K, Takahashi S. Complestatin, a potent anti-complement substance produced by Streptomyces lavendulae I. Fermentation, isolation and biological characterization. J Antibiot (Tokyo) 1989; 42: 236-241
    CrossrefPubMedGoogle Scholar
  • 22 Momota K, Kaneko I, Kimura S, Mitamura K, Shimada K. Inhibition of human immunodeficiency virus type-1-induced syncytium formation and cytopathicity by complestatin. Biochem Biophys Res Commun 1991; 179: 243-250
    CrossrefPubMedGoogle Scholar
  • 23 Goldstein JL, Basu SK, Brown MS. Receptor-mediated endocytosis of low density lipoprotein in cultured cells. Methods Enzymol 1983; 98: 241-260
    PubMedGoogle Scholar
  • 24 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedGoogle Scholar
  • 25 Hartert H, Schaeder JA. The physical and biological constants of thromb-elastography. Biorheology 1962; 01: 31-39
    CrossrefPubMedGoogle Scholar
  • 26 Kang YG, Martin DJ, Marquez J, Lewis JH, Bontempo FA, Shaw Jr RW, Starzl TE, Winter PM. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 1985; 64: 888-896
    PubMedGoogle Scholar
  • 27 Thorsen S. Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-aminocarboxylic acids. Biochim Biophys Acta 1975; 393: 55-65
    CrossrefPubMedGoogle Scholar
  • 28 Thorsen S, Clemmensen I, Sottrup-Jensen L, Magnusson S. Adsorption to fibrin of native fragments of known primary structure from human plasminogen. Biochim Biophys Acta 1981; 668: 377-387
    CrossrefPubMedGoogle Scholar
  • 29 Van ZonneveldA-J, Veerman H, Pannekoek H. On the interaction of the finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin. Inhibition of kringle-2 binding to fibrin by e-amino caproic acid. J Biol Chem 1986; 261: 14214-14218
    PubMedGoogle Scholar
  • 30 Ichinose A, Takio K, Fujikawa K. Localization of the binding site of tissue-type plasminogen activator to fibrin. J Clin Invest 1986; 78: 163-169
    CrossrefPubMedGoogle Scholar
  • 31 Kaneko I, Fearon DT, Austein KF. Inhibition of the alternative pathway of human complement in vitro by a natural product, complestatin. J Immunol 1980; 124: 1194-1198
    PubMedGoogle Scholar
  • 32 Pollanen J. Down-regulation of plasmin receptors on human sarcoma cells by glucocorticoids. J Biol Chem 1989; 264: 5628-5632
    PubMedGoogle Scholar
  • 33 Félez J, Miles LA, Plescia J, Plow EF. Regulation of plasminogen receptor expression on human monocytes and monocytoid cell lines. J Cell Biol 1990; 111: 1673-1683
    CrossrefPubMedGoogle Scholar
  • 34 Lu H, Li H, Mirshahi SS, Soria C, Soria J, Menashi S. Comparative study of fibrinolytic activity on U937 line after stimulation by interferon gamma 1,25-dihydroxy vitamin D3and their combination. Thromb Res 1993; 69: 353-359
    CrossrefPubMedGoogle Scholar
  • 35 Kim BS, Plow EF, Miles LA. Regulation of plasminogen receptor expression on monocytoid THP-1 cells by adherence to extracellular matrix proteins. Circulation 1992; 86: 1-148a (Abstract)
    CrossrefPubMedGoogle Scholar
  • 36 Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL. The cell biology of the plasminogen system. FASEB J 1995; 09: 939-945
    CrossrefPubMedGoogle Scholar
  • 37 Camacho M, Fondaneche MC, Burtin P. Limited proteolysis of tumor cells increases their plasmin-binding activity. FEBS Lett 1989; 245: 221-224
    PubMedGoogle Scholar
  • 38 Gonzalez-Gronow M, Stack S, Pizzo SV. Plasmin binding to the plasminogen receptor enhances catalytic efficiency and activates the receptor for subsequent ligand binding. Arch Biochem Biophys 1991; 286: 625-628
    CrossrefPubMedGoogle Scholar
  • 39 Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF. Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as candidate plasminogen receptor. Biochemistry 1991; 30: 1682-1691
    CrossrefPubMedGoogle Scholar
  • 40 Scott J. Thrombogenesis linked to atherogenesis at last? Nature. 1989; 341: 22-23
    PubMedGoogle Scholar